Market Overview

Biotech Reporter Adam Feuerstein Will Be On Benzinga's PreMarket Prep Friday Morning

Share:
Related IBB
Portfolio Manager Says Now Is A Great Time To Buy Biotech
Latest Tax Reform Bill From Senate GOP Seeks Repeal Of ACA Individual Mandate
3 Top Risks For Healthcare Investors (Seeking Alpha)

If you're a biotech trader or investor, you know who Adam Feuerstein is. The senior reporter for TheStreet, Inc. (NASDAQ: TST) is known across the biotech industry for his straight-shooting analysis, ability to cut through corporate jargon, and in-depth reporting on drug companies. Plus, there's his provacative Twitter feed. 

On Friday, March 10 at 9 a.m. ET, Feuerstein will join Benzinga's PreMarket Prep show to discuss the impact President Donald Trump could have on the industry, which biotech stocks are most vulnerable to pricing legislation, and his thoughts on the Novo Nordisk A/S (NYSE: NVO)—Global Blood Therapeutics Inc (NASDAQ: GBT) rumors. 

Have a question you want to ask? Create a free account and join our live chat before and during the interview. If you miss it live, you can also listen to the podcast after it's posted on Soundcloud

Posted-In: Adam Feuerstein Donald TrumpBiotech Previews Interview General

 

Related Articles (IBB + GBT)

View Comments and Join the Discussion!

Partner Center